Litcius/Paper detail

NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer

Bérengère Salomé, John P. Sfakianos, Daniel Ranti, Jorge Daza, Christine Bieber, Andrew Charap, Christian Hammer, Romain Banchereau, Adam M. Farkas, Dan Fu Ruan, Sudeh Izadmehr, Daniel Geanon, Geoffrey Kelly, Ronaldo M. de Real, Brian Lee, Kristin G. Beaumont, Sanjana Shroff, Yuanshuo A. Wang, Ying‐Chih Wang, Tin Htwe Thin, Mónica Garcı́a-Barros, Everardo Hegewisch-Solloa, Emily M. Mace, Li Wang, Timothy J. O’Donnell, Diego Chowell, Rubén Fernández‐Rodríguez, Mihaela Skobe, Nicole Taylor, Seunghee Kim‐Schulze, Robert Sebra, Doug Palmer, Eleanor Clancy‐Thompson, Scott A. Hammond, Alice O. Kamphorst, Karl‐Johan Malmberg, Emanuela Marcenaro, Pedro Romero, Rachel Brody, Mathias Viard, Yuko Yuki, Maureen P. Martin, Mary Carrington, Reza Mehrazin, Peter Wiklund, Ira Mellman, Sanjeev Mariathasan, Jun Zhu, Matthew D. Galsky, Nina Bhardwaj, Amir Horowitz

2022Cancer Cell128 citationsDOIOpen Access PDF

Topics & Concepts

BlockadeCD8ImmunotherapyImmune checkpointT-cell receptorCancer researchImmune systemCytotoxic T cellCancer immunotherapyT cellImmunologyHuman leukocyte antigenBladder cancerMedicineBiologyCancerAntigenReceptorInternal medicineIn vitroBiochemistryImmune Cell Function and InteractionCancer Immunotherapy and BiomarkersBladder and Urothelial Cancer Treatments
NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer | Litcius